8-K: Roche to Acquire 89bio for Up to $3.5 Billion

Roche Holdings, Inc. will acquire 89bio, Inc. for $14.50 per share in cash plus a contingent value right of up to $6.00 per share, totaling up to $3.5 billion.

Summary

• Roche Holdings, Inc. (Parent) will acquire 89bio, Inc. (Company) through a tender offer and subsequent merger.
• 89bio stockholders will receive $14.50 per share in cash at closing.
• Stockholders will also receive one non-tradeable Contingent Value Right (CVR) per share, potentially worth up to an additional $6.00 per share.
• The total transaction equity value is up to approximately $3.5 billion on a fully diluted basis.
• The offer price represents a premium of approximately 79% to 89bio's closing stock price on September 17, 2025, and a 52% premium to its 60-day volume-weighted average price.
• The transaction has been unanimously approved by 89bio's Board of Directors, which recommends stockholders tender their shares.
• Certain funds affiliated with RA Capital Management, L.P., holding approximately 13.4% of outstanding shares, have entered into a Tender and Support Agreement, agreeing to tender their shares.
• The closing is subject to customary conditions, including the tender of a majority of outstanding shares and regulatory review under the HSR Act, and is expected in the fourth quarter of 2025.

Sentiment

Score: 9

Explanation: The acquisition offers a significant premium to shareholders and includes CVRs for potential future upside, reflecting strong confidence in 89bio's lead asset, pegozafermin. The unanimous board approval and support from a major institutional investor further bolster positive sentiment. While CVRs introduce contingency, the overall deal structure is highly favorable for existing shareholders.

Positives

• The transaction offers a significant premium of 79% to 89bio's closing stock price on September 17, 2025, and a 52% premium to its 60-day volume-weighted average price.
• Stockholders will receive a guaranteed cash payment of $14.50 per share at closing.
• The inclusion of CVRs provides an opportunity for additional cash payments of up to $6.00 per share upon achievement of specified milestones, allowing participation in future commercial success.
• Pegozafermin, 89bio's lead candidate, is described as a 'potentially best-in-class' therapy for MASH, indicating strong asset value.
• Roche's established global development, manufacturing, and commercialization capabilities are expected to accelerate and maximize pegozafermin's potential benefit for patients.
• The transaction unlocks significant shareholder value, with a total equity value of up to approximately $3.5 billion.

Negatives

• CVR payments are contingent on future milestones, which are not guaranteed and carry inherent risks, including the possibility of no payments being made.
• The CVRs are non-tradeable, limiting liquidity and the ability for holders to realize their value before milestones are met.
• The transaction involves the loss of 89bio as an independent entity, potentially limiting future upside beyond the acquisition terms.

Risks

• Risks associated with the timing of the closing of the proposed transaction, including conditions not being satisfied within the expected timeframe or at all, or the closing not occurring.
• Uncertainties as to how many of 89bio's stockholders will tender their shares in the offer.
• The possibility that a governmental entity may prohibit, delay, or refuse to grant approval for the consummation of the transaction.
• The possibility that competing offers will be made.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the transaction.
• The outcome of any legal proceedings that may be instituted against the parties and others related to the merger agreement.
• Unanticipated difficulties or expenditures relating to the proposed transaction.
• The response of business partners and competitors to the announcement of the proposed transaction.
• Potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction.
• Risks related to non-achievement of the CVR milestones, meaning holders of the CVRs may not receive payments.
• Parent's obligation to use 'Commercially Reasonable Efforts' for Milestone 1 (First Commercial Sale in the United States for Stage 4 MASH) terminates on March 31, 2030, or upon achievement, and does not guarantee milestone achievement.
• The CVRs are non-tradeable, limiting liquidity for holders.

Future Outlook

The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions including majority tender and regulatory approvals. Roche is committed to using commercially reasonable efforts to achieve the first CVR milestone related to the First Commercial Sale of pegozafermin in Stage 4 MASH in the United States by March 31, 2030. However, there is no assurance that any CVR milestones will be achieved or that any CVR payments will be made.

Management Comments

• "Our mission at 89bio has always been to develop innovative therapies to help patients with serious liver and cardiometabolic diseases, a commitment demonstrated by the strategic design and successful execution of the development program for pegozafermin over the years. We are thrilled to be joining with Roche to combine the promise of pegozafermin with Roches established global development, manufacturing, and commercialization capabilities, to accelerate and maximize potential benefit for patients in need and unlock significant shareholder value. I am tremendously proud of the entire team at 89bio and would like to express my deepest thanks and gratitude to them, our Board, investigators, clinical trial participants, numerous vendors, and MASH and SHTG communities for helping us reach this pivotal moment." Rohan Palekar, CEO of 89bio.
• "We are excited about this agreement and to further develop this promising therapy, which we hope will provide people with moderate to severe MASH a new treatment option. By adding pegozafermin to our cardiovascular, renal, and metabolism portfolio and with our Diagnostics expertise in cardiovascular and metabolic diseases, we are aiming to transform the standard of care and positively impact patients lives." Boris L. Zatra, Head of Roche Corporate Business Development.

Industry Context

This acquisition highlights the increasing strategic value of innovative therapies for metabolic dysfunction-associated steatohepatitis (MASH), a significant unmet medical need. Roche's move to acquire 89bio and its lead candidate, pegozafermin, positions Roche to strengthen its cardiovascular, renal, and metabolism portfolio, leveraging its extensive global development and commercialization infrastructure. The structure of the deal, including CVRs tied to commercial and sales milestones, reflects a common trend in biopharmaceutical M&A, where buyers mitigate risk while offering sellers participation in future success, particularly for late-stage clinical assets like pegozafermin which is in Phase 3 trials.

Corporate Governance

Stakeholder Impact

• Shareholders will receive a significant premium in cash and potential additional payments via non-tradeable CVRs, representing a substantial return on investment.
• Covered Employees will receive substantially comparable cash compensation and benefits for one year post-closing, with service credit for eligibility and vesting in Parent Plans. However, there is a risk of 'potential difficulties in employee retention' due to the announcement.
• Customers/Patients are expected to benefit from accelerated development and commercialization of pegozafermin for MASH due to Roche's global capabilities.
• Business Partners and Competitors may experience shifts in relationships and competitive dynamics within the MASH treatment market following the announcement.

Next Steps

• Merger Sub will commence a tender offer no later than October 1, 2025.
• 89bio will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• The tender offer will initially remain open for 20 business days.
• Following the completion of the tender offer, Merger Sub will merge with 89bio.
• The transaction is expected to close in the fourth quarter of 2025.
• Parent and a Rights Agent will enter into a CVR Agreement at or prior to the Acceptance Time.
• 89bio will take actions to delist shares from NASDAQ and deregister under the Exchange Act as promptly as practicable after the Effective Time.
• 89bio will seek a tax ruling from the Israel Tax Authority (ITA) regarding Section 102 Shares and Awards.

Key Dates

Recommendation

The acquisition offers a substantial premium of 79% to the last closing price and 52% to the 60-day VWAP, providing immediate and significant value to shareholders. The inclusion of CVRs, while contingent, offers additional upside potential of up to $6.00 per share, allowing shareholders to participate in the future success of pegozafermin. The unanimous board approval and the support from a major institutional investor (RA Capital Management) further de-risk the transaction. Given the high premium and potential for additional CVR payments, tendering shares or acquiring shares to tender appears to be a strong investment decision.

Keywords

89bio, Roche, Merger, Acquisition, Tender Offer, CVR, Contingent Value Right, Pegozafermin, MASH, NASH, Biopharmaceutical, FGF21, Fibrosis, Cirrhosis, Healthcare, Biotech, Pharmaceuticals, ETNB